SCHEMBL2908050

SCHEMBL2908050

O=C(Oc1ccc(Oc2ccccc2)cc1)N1CCN2CCC1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.89
HTR3A P46098 1/20 0.89
CHRNA3 P32297 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7559030 0.94 CHRNA7 (1.00) CHRNA7HTR3ACHRNA3
SCHEMBL1781704 0.92 CHRNA7 (0.75) CHRNA7HTR3ACHRNA3
SCHEMBL4190184 0.91 CHRNA7 (0.78) CHRNA7HTR3ACHRNA3
SCHEMBL7556223 0.89 CHRNA7 (0.84) CHRNA7HTR3ACHRNA3
Fumaric Acid SCHEMBL1782407 0.87 CHRNA7 (0.68) CHRNA7HTR3ACHRNA3
SCHEMBL5914681 0.86 CHRNA7 (0.80) CHRNA7HTR3ACHRNA3
SCHEMBL4196882 0.86 CHRNA7 (0.75) CHRNA7HTR3ACHRNA3
SCHEMBL5914695 0.86 CHRNA7 (0.80) CHRNA7HTR3ACHRNA3
SCHEMBL2292551 0.85 CHRNA7 (0.78) CHRNA7HTR3ACHRNA3
SCHEMBL2292548 0.85 CHRNA7 (0.78) CHRNA7HTR3ACHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075983-A1 Novel Diazabicycloalkane Derivatives and Their Medical Use NEUROSEARCH A/S (DK) 2009-03-19 US claimed
EP-1987033-B1 DIAZABICYCLOALKANE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-08-25 EP disclosed
US-20090075983-A1 Novel Diazabicycloalkane Derivatives and Their Medical Use NEUROSEARCH A/S (DK) 2009-03-19 US disclosed
US-20020177591-A1 Pharmaceutical compositions for the treatment of CNS and other discorders PFIZER INC. 2002-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177591-A1 Pharmaceutical compositions for the treatment of CNS and other discorders CHRNA7, CHRNA5, CHRNA10 CHRNA7 1/4885HTR3A 98/4885CHRNA3 4/4885
US-20090075983-A1 Novel Diazabicycloalkane Derivatives and Their Medical Use CHRNA6, CHRNA2, CHRNA7 CHRNA7 3/4885HTR3A 165/4885CHRNA3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.